Luo Liying, Wei Qingquan, Liu Qing, Wang Li, Jiang Yanyun
Department of Ophthalmology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
Int J Gen Med. 2022 Sep 6;15:7077-7087. doi: 10.2147/IJGM.S380609. eCollection 2022.
Foldable capsular vitreous body (FCVB), a novel artificial vitreous substitute product, has been used clinically in recent years. The aim of this study was to evaluate the outcomes and complications of FCVB implantation surgery during the postoperative period.
We performed a prospective, nonrandomized study from November 2021 to March 2022. Eight patients with severe retinal detachment that could not be easily reattached were included in this study. Before and after surgery, visual acuity (VA), intraocular pressure (IOP), slit-lamp microscopy, optical coherence tomography (OCT), B-scan and CT were performed.
After the operation, the FCVB was well distributed in the vitreous cavity and supported the retina according to the B-scan and CT images. During the follow-up period, no vitreous hemorrhage or retinal detachment was found in any of the patients. On the first postoperative day, the average IOP increased from 9.6 ± 7.7 mmHg preoperatively to 13.8 ± 14.3 mmHg. Although the IOP of two patients fell outside the normal range, IOP was finally held steady after the fifth postoperative day in all cases. In addition, three patients (37.5%) experienced eye ache, and after taking a Saridon tablet, the pain was greatly alleviated. Moreover, no adverse events, such as silicone oil (SO) spillage and emulsification or serious complications, were observed.
The current vitreous substitute FCVB is effective and safe for treating complicated retinal detachments in ophthalmic applications. Further multiple-center clinical designs should focus on indications and complications of FCVB during long-term follow-up periods.
可折叠囊袋式玻璃体（FCVB）是一种新型人工玻璃体替代产品，近年来已在临床上应用。本研究的目的是评估FCVB植入手术后的疗效和并发症。
我们于2021年11月至2022年3月进行了一项前瞻性、非随机研究。本研究纳入了8例难以复位的严重视网膜脱离患者。手术前后进行了视力（VA）、眼压（IOP）、裂隙灯显微镜检查、光学相干断层扫描（OCT）、B超和CT检查。
术后，根据B超和CT图像，FCVB在玻璃体腔内分布良好并支撑视网膜。在随访期间，所有患者均未发现玻璃体出血或视网膜脱离。术后第一天，平均眼压从术前的9.6±7.7 mmHg升高至13.8±14.3 mmHg。虽然两名患者的眼压超出正常范围，但所有病例在术后第五天之后眼压最终保持稳定。此外，三名患者（37.5%）出现眼痛，服用去痛片后疼痛明显缓解。而且，未观察到硅油（SO）渗漏和乳化等不良事件或严重并发症。
目前的玻璃体替代物FCVB在眼科应用中治疗复杂性视网膜脱离有效且安全。进一步的多中心临床设计应关注FCVB在长期随访期间的适应证和并发症。
